Aquestive Therapeutics, Inc. Class Action Lawsuit
Company: Aquestive Therapeutics, Inc.
Ticker: (NASDAQ) AQST
Class Action Period: June 16, 2025 - January 8, 2026
See If You Qualify For Monetary Reward
Join the Aquestive Therapeutics, Inc. Class Action Lawsuit
CLASS ACTION PERIOD
June 16, 2025 - January 8, 2026
Allegations
According to the complaint, defendants provided investors with positive statements while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Aquestive’s New Drug Application (NDA) for Anaphylm (Dibutepinephrine) sublingual film; pertinently, Aquestive concealed or otherwise minimized the significance of the human factors involved in the use and deployment of its sublingual film, such as packaging, use, administration, and labeling. On January 9, 2026, Aquestive announced that the Company was in receipt of a letter from the FDA identifying deficiencies that precluded labeling discussions for Anaphylm. Moreover, Aquestive revealed that the letter from the FDA confirmed that the Agency’s review of Anaphylm NDA was ongoing and no final decision had been made, which effectively delayed the approval of Anaphylm well beyond the January 31, 2026 Prescription Drug User Fee Act date. Following this news, the price of Aquestive’s common stock declined dramatically. From a closing market price of $6.21 per share on January 8, 2026, Aquestive’s stock price fell to $3.91 per share on January 9, 2026, a decline of over 37% in a single day.
Eligibility
To join the lawsuit, you must have experienced a loss on Aquestive shares purchased within the class period specified above.
Lead Plaintiff Deadline
If you suffered a loss in Aquestive Therapeutics, Inc. during the relevant time frame, you have until May 4, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Frequently Asked Questions
- How do I join the lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST)?
Investors who purchased shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) during the class period (June 16, 2025 - January 8, 2026) can join by submitting their transaction details through this case page.
- Ensure your purchase falls within the class period
- Provide basic transaction and loss details
- Submit your information before the deadline
The lead plaintiff deadline for this case is May 4, 2026, so investors should act quickly to protect their rights.
- Who is eligible for the Aquestive Therapeutics, Inc. lawsuit?
Anyone who bought shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) during June 16, 2025 - January 8, 2026 and suffered financial losses may qualify.
- What is the lead plaintiff deadline to join the Aquestive Therapeutics, Inc. case?
The lead plaintiff deadline for the Aquestive Therapeutics, Inc. lawsuit is May 4, 2026. Investors should act quickly to avoid missing this deadline.
- What is the class period for Aquestive Therapeutics, Inc.?
The class period for Aquestive Therapeutics, Inc. (NASDAQ: AQST) is June 16, 2025 - January 8, 2026, during which investors may have been affected by alleged misconduct.
- Can I still join the Aquestive Therapeutics, Inc. lawsuit if I sold my shares?
Yes. Investors who purchased Aquestive Therapeutics, Inc. shares during June 16, 2025 - January 8, 2026 may still qualify, even if they sold their shares later.
- How much compensation can I receive from the Aquestive Therapeutics, Inc. lawsuit?
Compensation depends on the total losses and the final settlement. Eligible investors in the Aquestive Therapeutics, Inc. case may receive a portion of the recovery.
- Do I need to pay to participate in the Aquestive Therapeutics, Inc. case?
No, most securities fraud cases involving Aquestive Therapeutics, Inc. operate on a contingency basis, meaning there are no upfront costs unless there is a recovery.
- Will I need to appear in court for the Aquestive Therapeutics, Inc. lawsuit?
In most cases, investors do not need to appear in court. The legal team manages the Aquestive Therapeutics, Inc. case on behalf of participants.
- What documents are required for the Aquestive Therapeutics, Inc. lawsuit?
To participate in the Aquestive Therapeutics, Inc. lawsuit, investors may need to provide transaction records, purchase dates, number of shares, and loss details.
- What happens after I submit my trade information for Aquestive Therapeutics, Inc.?
After submission, your details for the Aquestive Therapeutics, Inc. case will be reviewed, and you may be contacted regarding eligibility or next steps.
- Is this legal advice for the Aquestive Therapeutics, Inc. lawsuit?
No, this page provides information about the Aquestive Therapeutics, Inc. case and does not constitute legal advice or create an attorney-client relationship.
- Why should I act quickly on the Aquestive Therapeutics, Inc. case?
The lead plaintiff deadline for the Aquestive Therapeutics, Inc. lawsuit is May 4, 2026. If you are an investor, you may have the opportunity to seek appointment as lead plaintiff or remain an absent class member.
EXPLORE MORE CASES
REGENXBIO Inc.
RGNX
Lead Plaintiff Deadline: April 14, 2026
Class Period: February 9, 2022 - January 27, 2026
Nektar Therapeutics
NKTR
Lead Plaintiff Deadline: May 5, 2026
Class Period: February 26, 2025 - December 15, 2025